This “Leishmaniasis - Pipeline Insight, 2021” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Leishmaniasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).
"Leishmaniasis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leishmaniasis pipeline landscape is provided which includes the disease overview and Leishmaniasis treatment guidelines. The assessment part of the report embraces, in depth Leishmaniasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leishmaniasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Leishmaniasis R&D. The therapies under development are focused on novel approaches to treat/improve Leishmaniasis.
This segment of the Leishmaniasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
LXE408: Novartis
DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 - a first-in-class compound, discovered at Novartis with financial support from Wellcome - as a potential new oral treatment for visceral leishmaniasis. Currently, it is in Phase II stage of development.
GSK 3494245: GlaxoSmithKline
GSK 3494245 is a Proteasome inhibitor being developed by GlaxoSmithKline for the treatment of patients with Leishmaniasis. The drug is currently in phase 1 stage of development.
This segment of the report provides insights about the different Leishmaniasis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Leishmaniasis. The companies which have their Leishmaniasis drug candidates in the most advanced stage, i.e. phase II include, Novartis.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Leishmaniasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leishmaniasis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leishmaniasis drugs.
Geography Covered
- Global coverage
Leishmaniasis Understanding
Leishmaniasis: Overview
Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).
"Leishmaniasis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leishmaniasis pipeline landscape is provided which includes the disease overview and Leishmaniasis treatment guidelines. The assessment part of the report embraces, in depth Leishmaniasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leishmaniasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Leishmaniasis R&D. The therapies under development are focused on novel approaches to treat/improve Leishmaniasis.
Leishmaniasis Emerging Drugs Chapters
This segment of the Leishmaniasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leishmaniasis Emerging Drugs
LXE408: Novartis
DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 - a first-in-class compound, discovered at Novartis with financial support from Wellcome - as a potential new oral treatment for visceral leishmaniasis. Currently, it is in Phase II stage of development.
GSK 3494245: GlaxoSmithKline
GSK 3494245 is a Proteasome inhibitor being developed by GlaxoSmithKline for the treatment of patients with Leishmaniasis. The drug is currently in phase 1 stage of development.
Leishmaniasis: Therapeutic Assessment
This segment of the report provides insights about the different Leishmaniasis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Leishmaniasis
There are approx. 4+ key companies which are developing the therapies for Leishmaniasis. The companies which have their Leishmaniasis drug candidates in the most advanced stage, i.e. phase II include, Novartis.
Phases
This report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Leishmaniasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Leishmaniasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leishmaniasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leishmaniasis drugs.
Leishmaniasis Report Insights
- Leishmaniasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Leishmaniasis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Leishmaniasis drugs?
- How many Leishmaniasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leishmaniasis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Leishmaniasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Leishmaniasis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Novartis
- GlaxoSmithKline
- MedC Biopharma Corporation
- Drugs for Neglected Diseases Initiative Foundation
- Infan Industria Quimica Farmaceutica Nacional
Key Products
- LXE408
- GSK 3494245
- GSK 3186899
- DNDI 6148
- DMD 2010
- DNDI 6174
- 18-Methoxycoronaridine
Table of Contents
IntroductionExecutive Summary
Leishmaniasis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Leishmaniasis - Analytical Perspective
Mid Stage Products
- Comparative Analysis
LXE408: Novartis
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products
- Comparative Analysis
GSK 3494245: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Leishmaniasis Key Companies
Leishmaniasis Key Products
Leishmaniasis- Unmet Needs
Leishmaniasis- Market Drivers and Barriers
Leishmaniasis- Future Perspectives and Conclusion
Leishmaniasis Analyst Views
Leishmaniasis Key Companies
AppendixList of Tables
Table 1 Total Products for Leishmaniasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Leishmaniasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis
- GlaxoSmithKline
- MedC Biopharma Corporation
- Drugs for Neglected Diseases Initiative Foundation
- Infan Industria Quimica Farmaceutica Nacional
